Search

Reset

Status

Medical Condition

Displaying 1 - 2 of 2

A study for patients with advanced or recurrent solid tumors or lymphomas using study drug CX-072

Condition: Cancer / Lymphoma
Investigator: Naiyer Rizvi, MD
Status: Closed
This is the first study in humans for an investigational drug called CX-072. CX-072 is a Probody therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are created from antibodies.
Read More

Study of Dabrafenib, Trametinib, and Navitoclax in BRAF-Mutant Melanoma and Other Solid Tumors

Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the first part (Phase I) of the study is to test the safety of navitoclax in combination with dabrafenib and trametinibat different doses to find out what effects, if any, it has on people. There will be about 18 people treated in this part of the study. The purpose of the second part of this study (Phase II) is to compare the good and bad…
Read More